What is Evercore ISI's price target for BCRX?

Evercore ISI's latest stated price target for BioCryst Pharmaceuticals Inc. (BCRX) is $17, from its action on Feb 18, 2026.

What is Evercore ISI's rating on BCRX?

Evercore ISI rates BCRX Outperform, a bullish rating, as of Feb 18, 2026.

When did Evercore ISI last change its view on BCRX?

On Feb 18, 2026, Evercore ISI resumes coverage at Outperform, price target $17.

Analyst firms · Evercore ISI · BCRX

Evercore ISI BCRX price target and rating history

BioCryst Pharmaceuticals Inc. (BCRX) · Health Care

Evercore ISI rates BioCryst Pharmaceuticals Inc. (BCRX) Outperform with a $17 price target, as of its latest action on Feb 18, 2026. It has published 4 rating actions on BCRX since August 2022, including 1 upgrade and 2 downgrades.

Current rating: Outperform
Price target: $17
Median target, all firms: Too few
Actions on BCRX: 4

Evercore ISI price target on BCRX

Evercore ISI price target on BCRX, each point a stated target, August 2022 to February 2026.

Every Evercore ISI rating on BCRX

Feb 18, 2026
ResumeEvercore ISI resumes coverage at Outperform, price target $17
Oct 1, 2025
DowngradeEvercore ISI downgrades to In-line from Outperform, price target $8
Nov 2, 2022
UpgradeEvercore ISI upgrades to Outperform from In-line, price target $14 to $16
Aug 5, 2022
DowngradeEvercore ISI downgrades to In-line from Outperform, price target $14

How other firms rate BCRX

Each firm's latest rating and stated target in the last 12 months.

Firm	Rating	Price target	Date
RBC Capital Markets	Sector Perform	$11	Sep 10, 2026
Evercore ISI	Outperform	$17	Feb 18, 2026

Questions about Evercore ISI and BCRX

What is Evercore ISI's price target for BCRX?: Evercore ISI's latest stated price target for BioCryst Pharmaceuticals Inc. (BCRX) is $17, from its action on Feb 18, 2026.
What is Evercore ISI's rating on BCRX?: Evercore ISI rates BCRX Outperform, a bullish rating, as of Feb 18, 2026.
When did Evercore ISI last change its view on BCRX?: On Feb 18, 2026, Evercore ISI resumes coverage at Outperform, price target $17.

More BCRX rating histories

All Evercore ISI ratings BCRX news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.